MX2021015058A - Sistemas de casx artificiales. - Google Patents
Sistemas de casx artificiales.Info
- Publication number
- MX2021015058A MX2021015058A MX2021015058A MX2021015058A MX2021015058A MX 2021015058 A MX2021015058 A MX 2021015058A MX 2021015058 A MX2021015058 A MX 2021015058A MX 2021015058 A MX2021015058 A MX 2021015058A MX 2021015058 A MX2021015058 A MX 2021015058A
- Authority
- MX
- Mexico
- Prior art keywords
- casx
- variant
- engineered
- systems
- variants
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858750P | 2019-06-07 | 2019-06-07 | |
| US201962944892P | 2019-12-06 | 2019-12-06 | |
| US202063030838P | 2020-05-27 | 2020-05-27 | |
| PCT/US2020/036505 WO2020247882A1 (en) | 2019-06-07 | 2020-06-05 | Engineered casx systems |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021015058A true MX2021015058A (es) | 2022-04-06 |
Family
ID=71899867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015058A MX2021015058A (es) | 2019-06-07 | 2020-06-05 | Sistemas de casx artificiales. |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US11560555B2 (enExample) |
| EP (1) | EP3980533A1 (enExample) |
| JP (2) | JP7744011B2 (enExample) |
| KR (1) | KR20220032050A (enExample) |
| CN (1) | CN114375334B (enExample) |
| AU (1) | AU2020289591B2 (enExample) |
| BR (1) | BR112021024288A2 (enExample) |
| CA (1) | CA3142883A1 (enExample) |
| CL (1) | CL2021003233A1 (enExample) |
| GB (1) | GB2600274B (enExample) |
| IL (1) | IL288738A (enExample) |
| MX (1) | MX2021015058A (enExample) |
| PE (1) | PE20220256A1 (enExample) |
| PH (1) | PH12021553076A1 (enExample) |
| SG (1) | SG11202113253SA (enExample) |
| TW (1) | TW202113074A (enExample) |
| WO (1) | WO2020247882A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3841205A4 (en) * | 2018-08-22 | 2022-08-17 | The Regents of The University of California | VARIANT TYPE V CRISPR/CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF |
| SG11202113253SA (en) | 2019-06-07 | 2021-12-30 | Scribe Therapeutics Inc | Engineered casx systems |
| US12551560B2 (en) | 2019-09-09 | 2026-02-17 | Scribe Therapeutics Inc. | Compositions and methods for use in immunotherapy |
| EP4028522A1 (en) | 2019-09-09 | 2022-07-20 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of sod1 |
| WO2021113763A1 (en) | 2019-12-06 | 2021-06-10 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of rhodopsin |
| JP2023510352A (ja) * | 2020-01-10 | 2023-03-13 | スクライブ・セラピューティクス・インコーポレイテッド | Ｐｃｓｋ９の標的化のための組成物および方法 |
| MX2022011460A (es) | 2020-03-18 | 2022-12-15 | Scribe Therapeutics Inc | Composiciones y métodos para el direccionamiento de c9orf72. |
| GB202010075D0 (en) * | 2020-07-01 | 2020-08-12 | Imp College Innovations Ltd | Therapeutic nucleic acids, peptides and uses |
| WO2022119957A1 (en) | 2020-12-02 | 2022-06-09 | The Regents Of The University Of California | Crispr-cas effector polypeptides and methods of use thereof |
| AU2021392719B2 (en) | 2020-12-03 | 2025-08-14 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
| US20240100185A1 (en) | 2020-12-03 | 2024-03-28 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of ptbp1 |
| KR20230129395A (ko) | 2020-12-09 | 2023-09-08 | 스크라이브 테라퓨틱스 인크. | 유전자 편집을 위한 aav 벡터 |
| AU2022234760A1 (en) | 2021-03-09 | 2023-09-14 | Arbor Biotechnologies, Inc. | Compositions comprising a variant polypeptide and uses thereof |
| AU2022284804A1 (en) | 2021-06-01 | 2023-12-07 | Arbor Biotechnologies, Inc. | Gene editing systems comprising a crispr nuclease and uses thereof |
| WO2022261150A2 (en) | 2021-06-09 | 2022-12-15 | Scribe Therapeutics Inc. | Particle delivery systems |
| IL311610A (en) * | 2021-09-21 | 2024-05-01 | Scribe Therapeutics Inc | Engineered CASX suppressor systems |
| EP4405490A2 (en) | 2021-09-23 | 2024-07-31 | Scribe Therapeutics Inc. | Self-inactivating vectors for gene editing |
| CN116497002A (zh) * | 2022-01-19 | 2023-07-28 | 中国科学院动物研究所 | 工程化的CasX核酸酶、效应蛋白及其用途 |
| CA3257824A1 (en) | 2022-06-02 | 2023-12-07 | Scribe Therapeutics Inc. | MODIFIED TYPE V, CLASS 2 CRISPR SYSTEMS |
| WO2023235888A2 (en) | 2022-06-03 | 2023-12-07 | Scribe Therapeutics Inc. | COMPOSITIONS AND METHODS FOR CpG DEPLETION |
| EP4536819A1 (en) | 2022-06-07 | 2025-04-16 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
| WO2023240027A1 (en) | 2022-06-07 | 2023-12-14 | Scribe Therapeutics Inc. | Particle delivery systems |
| CN119998446A (zh) * | 2022-06-07 | 2025-05-13 | 斯克里贝治疗公司 | 用于靶向pcsk9的组合物和方法 |
| EP4536286A1 (en) | 2022-06-08 | 2025-04-16 | Scribe Therapeutics Inc. | Aav vectors for gene editing |
| WO2023240157A2 (en) | 2022-06-08 | 2023-12-14 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of dmd |
| US20260139236A1 (en) * | 2022-10-11 | 2026-05-21 | The Broad Institute, Inc. | Reprogramable tnpb polypeptides and use thereof |
| US20260232844A1 (en) | 2023-02-15 | 2026-08-13 | Arbor Biotechnologies, Inc. | Gene editing method for inhibiting aberrant splicing in stathmin 2 (stmn2) transcript |
| WO2024192291A1 (en) | 2023-03-15 | 2024-09-19 | Renagade Therapeutics Management Inc. | Delivery of gene editing systems and methods of use thereof |
| WO2024206620A1 (en) | 2023-03-29 | 2024-10-03 | Scribe Therapeutics Inc. | Messenger rna encoding casx |
| WO2024206676A1 (en) | 2023-03-29 | 2024-10-03 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of lpa |
| WO2024206555A1 (en) * | 2023-03-29 | 2024-10-03 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
| TW202444914A (zh) | 2023-03-29 | 2024-11-16 | 美商斯奎柏治療公司 | 抑制子融合蛋白系統 |
| CN116926043B (zh) * | 2023-04-28 | 2024-09-06 | 新乡医学院第三附属医院 | 一种dCasX蛋白核酸酶、重组载体及其应用 |
| WO2024228975A2 (en) * | 2023-05-02 | 2024-11-07 | Inari Agriculture Technology, Inc. | Ribozyme sequences for processing rna |
| JP2026523341A (ja) | 2023-05-15 | 2026-07-14 | エヌクロマ・バイオ，インコーポレーテッド | Ｈｂｖ遺伝子発現のエピジェネティック調節のための組成物および方法 |
| EP4729547A1 (en) * | 2023-06-16 | 2026-04-22 | VCGT Inc. | Zinc finger protein, zinc finger nuclease, vector, and genome editing method using said substances |
| EP4771154A2 (en) | 2023-09-01 | 2026-07-08 | Renagade Therapeutics Management Inc. | Gene editing systems, compositions, and methods for treatment of vexas syndrome |
| WO2025072293A1 (en) | 2023-09-27 | 2025-04-03 | Scribe Therapeutics Inc. | Optimized mrnas encoding casx proteins |
| CN117296799B (zh) * | 2023-11-28 | 2024-02-02 | 四川省医学科学院·四川省人民医院 | 一种视网膜色素变性疾病模型的构建方法及其应用 |
| WO2025171210A1 (en) | 2024-02-09 | 2025-08-14 | Arbor Biotechnologies, Inc. | Compositions and methods for gene editing via homology-mediated end joining |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025240940A1 (en) | 2024-05-17 | 2025-11-20 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of apolipoprotein c3 |
| WO2026015832A2 (en) | 2024-07-12 | 2026-01-15 | Arbor Biotechnologies, Inc. | Reverse transcriptases and gene editing systems comprising such |
| WO2026015829A2 (en) | 2024-07-12 | 2026-01-15 | Arbor Biotechnologies, Inc. | Small reverse transcriptases and gene editing systems comprising such |
| CN120424908B (zh) * | 2025-07-10 | 2025-09-12 | 南京农业大学 | 一种基于LAMP与CRISPR/Cas的检测方法和应用 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| ATE219660T1 (de) | 1994-09-30 | 2002-07-15 | Inex Pharmaceuticals Corp | Mittel zum einbringen polyanionischer materialien in zellen |
| US5695937A (en) | 1995-09-12 | 1997-12-09 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
| US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
| CA2597724A1 (en) | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Cationic lipids and formulated molecular compositions containing them |
| EP3100718B1 (en) | 2008-01-02 | 2019-11-27 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
| EP2279254B1 (en) | 2008-04-15 | 2017-07-05 | Protiva Biotherapeutics Inc. | Novel lipid formulations for nucleic acid delivery |
| US9221902B2 (en) | 2008-11-07 | 2015-12-29 | Fabrus, Inc. | Combinatorial antibody libraries and uses thereof |
| WO2010075303A1 (en) | 2008-12-23 | 2010-07-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same |
| US20110071208A1 (en) | 2009-06-05 | 2011-03-24 | Protiva Biotherapeutics, Inc. | Lipid encapsulated dicer-substrate interfering rna |
| ES2613498T3 (es) | 2009-07-01 | 2017-05-24 | Protiva Biotherapeutics Inc. | Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos |
| US9580714B2 (en) | 2010-11-24 | 2017-02-28 | The University Of Western Australia | Peptides for the specific binding of RNA targets |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| CA2953341C (en) | 2014-06-25 | 2023-01-24 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| CA2969619A1 (en) | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
| EP3247328B1 (en) | 2015-01-21 | 2026-01-07 | Genevant Sciences Gmbh | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| CA3012631A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
| HUE067372T2 (hu) | 2015-06-29 | 2024-10-28 | Acuitas Therapeutics Inc | Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására |
| CN116814590A (zh) | 2015-10-22 | 2023-09-29 | 布罗德研究所有限公司 | Vi-b型crispr酶和系统 |
| CN108368028B (zh) | 2015-10-28 | 2021-09-03 | 爱康泰生治疗公司 | 用于递送核酸的新型脂质和脂质纳米颗粒制剂 |
| EP3374494A4 (en) | 2015-11-11 | 2019-05-01 | Coda Biotherapeutics, Inc. | CRISPR COMPOSITIONS AND METHODS OF USE THEREOF FOR GENE THERAPY |
| EP3390624A4 (en) | 2015-12-18 | 2019-07-10 | The Regents of The University of California | Modified site-directed modifying polypeptides and methods of use thereof |
| US9896696B2 (en) | 2016-02-15 | 2018-02-20 | Benson Hill Biosystems, Inc. | Compositions and methods for modifying genomes |
| WO2017212007A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Cationic carriers for nucleic acid delivery |
| EP3468612A1 (en) | 2016-06-09 | 2019-04-17 | CureVac AG | Hybrid carriers for nucleic acid cargo |
| CN109688820B (zh) | 2016-06-24 | 2023-01-10 | 科罗拉多州立大学董事会（法人团体） | 用于生成条形码化组合文库的方法 |
| WO2018035250A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Methods for identifying class 2 crispr-cas systems |
| JP2019532644A (ja) | 2016-09-30 | 2019-11-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｒｎａ誘導型核酸修飾酵素及びその使用方法 |
| US9982267B2 (en) | 2016-10-12 | 2018-05-29 | Feldan Bio Inc. | Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same |
| EP3568470B1 (en) | 2017-01-10 | 2022-07-06 | Christiana Care Health Services, Inc. | Methods for in vitro site-directed mutagenesis using gene editing technologies |
| US20190367924A1 (en) * | 2017-02-17 | 2019-12-05 | Temple University - Of The Commonwealth System Of Higher Education | Gene editing therapy for hiv infection via dual targeting of hiv genome and ccr5 |
| MX2019011215A (es) | 2017-03-24 | 2020-02-12 | Curevac Ag | Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos. |
| US11773409B2 (en) | 2017-04-21 | 2023-10-03 | The Board Of Trustees Of The Leland Stanford Junior University | CRISPR/Cas 9-mediated integration of polynucleotides by sequential homologous recombination of AAV donor vectors |
| WO2019084148A1 (en) | 2017-10-25 | 2019-05-02 | Monsanto Technology Llc | TARGETED RNA GUIDED ENDONUCLEASE ENDONUCLEASE ACTIVITY IN EUKARYOTES |
| US10253365B1 (en) | 2017-11-22 | 2019-04-09 | The Regents Of The University Of California | Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs |
| EP3758714A4 (en) | 2018-02-27 | 2021-12-01 | The University of North Carolina at Chapel Hill | METHODS AND COMPOSITIONS FOR TREATMENT OF ANGELMAN'S SYNDROME |
| US20200224160A1 (en) | 2018-02-27 | 2020-07-16 | Sorrento Therapeutics, Inc. | Process for dna integration using rna-guided endonucleases |
| US12522811B2 (en) | 2018-05-01 | 2026-01-13 | The Children's Medical Center Corporation | Enhanced BCL11A RNP / CRISPR delivery and editing using a 3XNLS-CAS9 |
| US20210139892A1 (en) | 2018-07-05 | 2021-05-13 | The Regents Of The University Of California | Compositions and methods for delivery of rna to a cell |
| US20210284981A1 (en) | 2018-07-24 | 2021-09-16 | The Regents Of The University Of California | Rna-guided nucleic acid modifying enzymes and methods of use thereof |
| EP3841205A4 (en) | 2018-08-22 | 2022-08-17 | The Regents of The University of California | VARIANT TYPE V CRISPR/CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF |
| SG11202113253SA (en) | 2019-06-07 | 2021-12-30 | Scribe Therapeutics Inc | Engineered casx systems |
| WO2020247883A2 (en) | 2019-06-07 | 2020-12-10 | Scribe Therapeutics Inc. | Deep mutational evolution of biomolecules |
| WO2021007177A1 (en) | 2019-07-08 | 2021-01-14 | The Regents Of The University Of California | Variant type v crispr/cas effector polypeptides and methods of use thereof |
| AU2020324386B2 (en) | 2019-08-02 | 2026-04-23 | Monsanto Technology Llc | Methods and compositions to promote targeted genome modifications using HUH endonucleases |
| US12551560B2 (en) | 2019-09-09 | 2026-02-17 | Scribe Therapeutics Inc. | Compositions and methods for use in immunotherapy |
| EP4028522A1 (en) | 2019-09-09 | 2022-07-20 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of sod1 |
| IL292571A (en) | 2019-10-28 | 2022-06-01 | Targetgene Biotechnologies Ltd | Pam-reduced and pam-abolished cas derivatives compositions and uses thereof in genetic modulation |
| WO2021113763A1 (en) | 2019-12-06 | 2021-06-10 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of rhodopsin |
| WO2021113772A1 (en) | 2019-12-06 | 2021-06-10 | Scribe Therapeutics Inc. | Particle delivery systems |
| EP4069846A1 (en) | 2019-12-07 | 2022-10-12 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of htt |
| JP2023510352A (ja) | 2020-01-10 | 2023-03-13 | スクライブ・セラピューティクス・インコーポレイテッド | Ｐｃｓｋ９の標的化のための組成物および方法 |
| MX2022011460A (es) | 2020-03-18 | 2022-12-15 | Scribe Therapeutics Inc | Composiciones y métodos para el direccionamiento de c9orf72. |
| AU2021392719B2 (en) | 2020-12-03 | 2025-08-14 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
| WO2022261150A2 (en) | 2021-06-09 | 2022-12-15 | Scribe Therapeutics Inc. | Particle delivery systems |
| IL311610A (en) | 2021-09-21 | 2024-05-01 | Scribe Therapeutics Inc | Engineered CASX suppressor systems |
| EP4405490A2 (en) | 2021-09-23 | 2024-07-31 | Scribe Therapeutics Inc. | Self-inactivating vectors for gene editing |
| CA3257824A1 (en) | 2022-06-02 | 2023-12-07 | Scribe Therapeutics Inc. | MODIFIED TYPE V, CLASS 2 CRISPR SYSTEMS |
-
2020
- 2020-06-05 SG SG11202113253SA patent/SG11202113253SA/en unknown
- 2020-06-05 CN CN202080056141.9A patent/CN114375334B/zh active Active
- 2020-06-05 PE PE2021002050A patent/PE20220256A1/es unknown
- 2020-06-05 JP JP2021572556A patent/JP7744011B2/ja active Active
- 2020-06-05 AU AU2020289591A patent/AU2020289591B2/en active Active
- 2020-06-05 CA CA3142883A patent/CA3142883A1/en active Pending
- 2020-06-05 PH PH1/2021/553076A patent/PH12021553076A1/en unknown
- 2020-06-05 EP EP20750444.0A patent/EP3980533A1/en active Pending
- 2020-06-05 BR BR112021024288A patent/BR112021024288A2/pt unknown
- 2020-06-05 TW TW109119111A patent/TW202113074A/zh unknown
- 2020-06-05 KR KR1020227000734A patent/KR20220032050A/ko active Pending
- 2020-06-05 MX MX2021015058A patent/MX2021015058A/es unknown
- 2020-06-05 WO PCT/US2020/036505 patent/WO2020247882A1/en not_active Ceased
- 2020-06-05 GB GB2200132.5A patent/GB2600274B/en active Active
-
2021
- 2021-11-23 US US17/533,997 patent/US11560555B2/en active Active
- 2021-12-03 US US17/542,219 patent/US20220220508A1/en not_active Abandoned
- 2021-12-06 CL CL2021003233A patent/CL2021003233A1/es unknown
- 2021-12-06 IL IL288738A patent/IL288738A/en unknown
-
2022
- 2022-11-22 US US18/058,251 patent/US12084692B2/en active Active
-
2024
- 2024-07-19 US US18/778,393 patent/US20250043262A1/en active Pending
- 2024-10-08 US US18/909,093 patent/US20250136962A1/en active Pending
-
2025
- 2025-09-04 JP JP2025147107A patent/JP2025183286A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7744011B2 (ja) | 2025-09-25 |
| PH12021553076A1 (en) | 2023-08-14 |
| CA3142883A1 (en) | 2020-12-10 |
| US20230124880A1 (en) | 2023-04-20 |
| JP2022534809A (ja) | 2022-08-03 |
| BR112021024288A2 (pt) | 2022-02-15 |
| US20250043262A1 (en) | 2025-02-06 |
| EP3980533A1 (en) | 2022-04-13 |
| PE20220256A1 (es) | 2022-02-21 |
| US12084692B2 (en) | 2024-09-10 |
| GB2600274A (en) | 2022-04-27 |
| KR20220032050A (ko) | 2022-03-15 |
| US11560555B2 (en) | 2023-01-24 |
| US20250136962A1 (en) | 2025-05-01 |
| JP2025183286A (ja) | 2025-12-16 |
| WO2020247882A1 (en) | 2020-12-10 |
| US20220220508A1 (en) | 2022-07-14 |
| CN114375334A (zh) | 2022-04-19 |
| TW202113074A (zh) | 2021-04-01 |
| CN114375334B (zh) | 2026-03-20 |
| CL2021003233A1 (es) | 2022-08-12 |
| US20220081681A1 (en) | 2022-03-17 |
| SG11202113253SA (en) | 2021-12-30 |
| IL288738A (en) | 2022-02-01 |
| GB2600274B (en) | 2024-11-27 |
| AU2020289591A1 (en) | 2021-12-23 |
| AU2020289591B2 (en) | 2026-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021553076A1 (en) | Engineered casx systems | |
| SA520420729B1 (ar) | الأحماض النووية الريبوزية الدليلية المُعدلة لتصحيح الجين | |
| ZA202202628B (en) | Novel crispr dna targeting enzymes and systems | |
| IL281305A (en) | Proteins that bind CD16, NKG2D, and CCR4, EGFR, or PD-L1 | |
| MY204756A (en) | Factor viii chimeric proteins and uses thereof | |
| EP4361261A3 (en) | Novel cas13b orthologues crispr enzymes and systems | |
| WO2020236972A3 (en) | Non-classi engineered crispr-cas polynucleotide targeting system | |
| ZA201908445B (en) | Recombinant adenoviruses carrying transgenes | |
| PH12018501280A1 (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use | |
| MX377162B (es) | Nuevas enzimas y sistemas crispr | |
| MX2019007020A (es) | Anticuerpos il-11. | |
| TR201909037T4 (tr) | Yeni protein deamidaz. | |
| EP4667565A3 (en) | Methods and compositions for the treatment of fabry disease | |
| WO2018148486A8 (en) | Anti-factor d antibodies and uses thereof | |
| MX2017009937A (es) | Cepas fungicas y metodos de uso. | |
| EP4628631A3 (en) | Conditional primer extension for single-molecule detection | |
| EP2544427A3 (en) | Collaboration privacy | |
| EA201791918A1 (ru) | Модификация белков клеток-хозяев | |
| WO2021007504A3 (en) | Methods and compositions comprising reduced level of host cell proteins | |
| WO2014150748A3 (en) | Stabilized single human cd4 domains and fusion proteins | |
| WO2020115083A3 (fr) | Amphipols | |
| PH12017502323A1 (en) | Novel xylanase | |
| PH12020551519A1 (en) | Bamboo connector system | |
| MY191745A (en) | Efficient selectivity of recombinant proteins | |
| WO2019193321A3 (en) | Degradable carrier nucleic acid for use in the extraction, precipitation and/or purification of nucleic acids |